The stock market briefly boomed on Tuesday, with the S&P 500 surging as much as 4% before turning slightly negative.

A swift 11% decline in the benchmark index since President Donald Trump's "Liberation Day" last week was enough for investors to hold their noses and buy stocks, on the hunt for deals.

Some of Tuesday's best-performing stocks were in the financials, technology, utilities, and industrials sectors, but the gains later evaporated.

According to data from Bank of America , all cohorts of its client groups, including institutional clients, corporate clients, and private clients, bought the dip in stocks last week.

"Clients were net buyers of $8.0B of US equities, the fourth-largest weekly inflow in our data history since '08," Bank of America said in a note on Tuesday.

Analysts see opportunities

Wall Street analysts were quick to pounce on the downside volatility, with many research desks advocating for clients to take advantage of the decline in valuations to go bargain hunting.

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral," and another 22 companies were initiated or resumed coverage with a buy rating, Briefing.com data showed.

Here's where Wall Street is seeing opportunity.

Apple looks attractive after a steep plunge

Analysts at Bank of America said shares of Apple looked appealing as its valuation took a hit amid the tariff-related decline.

The stock is down 31% from its 52-week high.

"The pullback presents a particularly enhanced buying opportunity for investors to own a high-quality name," analysts at the bank said, adding that the risk/reward profile of the stock typically "skews positive" when its forward price-to-earnings multiple drops below 25 times.

It sits at about 22 times.

Analysts are encouraged by Apple's stable cash flows and earnings resiliency and view the company as a prospective beneficiary of AI adoption trends.

The bank rates Apple at a buy with a $250 price target.

GLP-1 weight-loss drugs

Analysts at Goldman Sachs believe the 21% decline in Eli Lilly stock since early March is a great buying opportunity.

"At current levels, we see a compelling entry point into the sector's premier topline grower," the bank said.